OIP	E veres
MAY 1	9 7004 E
13/10	and the second

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE BAREST THE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449/PTO Application Number 10/695,577 Filing Date 10/28/2003 INFORMATION DISCLOSURE First Named Inventor Edwin R. Chapman STATEMENT BY APPLICANT Art Unit 1645 (Use as many sheets as necessary) Examiner Name Attorney Docket Number 960296.99004 Sheet

		1	U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Number Kind Code ^{2 (f snow)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-	\		
		US-			
		US-			
		US-			·
		UŞ-			
		US-			
		US-	`	<u> </u>	
		US-			
		US-			
		US-			
-	ſ	US-			
_		US-			
		US-		l \	

			FO	REIGN PAT	ENT DOCU	MENTS		
Examiner Initials*	Cite No.	Foreign Patent Documen	t	P	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	_ ا
		Country Code ³ "Number ⁴ "Kind Code ⁸ (# known)		ММ	-DD-YYYY		Or Relevant Figures Appear	
						1		
			7.	7			<u> </u>	上
				7				L
		n/	1) 1 0 0	/				

Examiner
Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicants unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *See thinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *See Kinds Codes of USPTO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		a required to respond to a some	of information unless it contains a valid OM8 control number. Complete if Known		
Substit	ite for form 1449/PTO			Application Number	10/695,577
INF	ORMATION	N DIS	CLOSURE	Filing Date	10/28/2003
STA	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	PPLICANT	First Named Inventor	Edwin R. Chapman	
			Art Unit	1645	
	(Use as many sheets as necessary)		necessary)	Examiner Name	_
Sheet	2	of	4	Attorney Docket Number	960296.99004

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS					
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of					
W	1	J. BAI, et al. Membrane-embedded synaptotagmin penetrates cis or trans target membranes and clusters via a novel mechanism. J Biol Chem 275: 25427-35 (2000).					
1	2	E.R. CHAPMAN. Synaptotagmin: a Ca(2+) sensor that triggers exocytosis? Nat Rev Mol Cell Biol 3: 498-508 (2002).					
	3	E.R. CHAPMAN, et al. A novel function for the second C2 domain of synaptotagmin. Ca2+-triggered dimerization. J Biol Chem 271:5844-49 (1996).					
	4	D. DEMEMES, et al. Efferent function of vestibular afferent endings? Similar localizationi of N-type calcium channels, synaptic vesicle and synaptic membrane-associated proteins. Neuroscience 98: 377-84 (2000).					
	5	M. FUKUDA, et al. Mechanism of the SDS-resistant synaptotagmin clustering mediated by the cystelne cluster at the interface between the transmembrane and spacer domains. J Biol Chem 276: 40319-25 (2001).					
	6.	M. FUKUDA, et al. Synaptotagmin IX regulates Ca2+-dependent secretion in PC12 cells. J Biol Chem 277: 4601-04 (2002).					
	7	M. FUKUDA, et al. Distinct self-oligomerization activities of synaptotagmin family. Unique calcium-dependent oligomerization properties of synaptotagmin VII. J Biol Chem 275: 28180-85 (2000).					
	8	A. GUT, et al. Expression and localisation of synaptotagmin isoforms in endocrine ß-cells: their function in insulin exocytosis. Journal of Cell Science 114(9): 1709-16 (2001)					
	9	P. JUZANS, et al. Synaptotagmin II immunoreactivity in normal and botulinum type-A treated mouse motor nerve terminals. Pflugers Arch 431: R283-84 (1996).					
$\sqrt{}$	10	S. KOZAKI, et al. Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Microb Pathog 25: 91-99 (1998).					

	 			/			
Examiner Signature	Mena	1-1	100	Date Considered	11/	26/8	25

^{*}EXAMINER: Initial if refdence considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2/Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98! The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a veild OMB control number.

			CC OT 1000, NO PERSONS AS	o ragaired to respend to a series	Complete if Known	
Substitu	te for form 1449/P1	10		Application Number	10/695,577	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Filling Date First Named Art Unit Examiner Named Attorney Dock	Filing Date	10/28/2003				
		RMATION DISCLOSURE EMENT BY APPLICANT (Use as many sheets as necessary)	First Named Inventor	Edwin R. Chapman		
				Art Unit	1645	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Examiner Name	_			
Sheet	3	of	4	Attorney Docket Number	960296.99004	

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	I tocked name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	T²
11 prote		J.L. LEWIS, et al. The transmembrane domain of syntaxin 1A is critical for cytoplasmic domain protein-protein interactions. J Biol Chem 276: 15458-65 (2001).	
	12	L. LI, et al. Isolation of synaptotagmin as a receptor for types A and E botulinum neurotoxin and analysis of their comparative binding using a new microtiter plate assay. J Nat Toxins 7: 215-26 (1998).	
	13	M. MATTEOLI, et al. Exo-endocytotic recycling of synaptic vesicles in developing processes of cultured hippocampal neurons. J Cell Biol 117: 849-61 (1992).	
	14	T. NISHIKI, et al. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem 269: 10498-503 (1994).	
	15	T. NISHIKI, et al. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett 378: 253-57 (1996).	
	16	T. NISHIKI, et al. Binding of botulinum type B neurotoxin to Chinese hamster ovary cells transfected with rat synaptotagmin II cDNA. Neurosci Lett 208: 105-08 (1996).	
	17	S.L. OSBORNE, et al. Calcium-dependent oligomerization of synaptotagmins I and II. Synaptotagmins I and II are localized on the same synaptic vesicle and heterodimerize in the presence of calcium. J Biol Chem 274: 59-66 (1999).	
	18	M.S. PERIN, et al. Phospholipid binding by a synaptic vesicle protein homologous to the regulatory region of protein kinase C. Nature 345: 260-63 (1990).	
	19	G. SCHIAVO, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359: 832-35 (1992).	
V	20	G. SCHIAVO, et al. Synaptotagmins: more isoforms than functions? Biochem Biophys Res Commun 248: 1-8 (1998).	

	<u> </u>		<u> </u>				
Examiner Signature	lanessay	17	vo	Date Considered	11/	26/	05

*EXAMINER: Initial if reference considered, whether or not clastion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/695,577 INFORMATION DISCLOSURE Filing Date 10/28/2003 STATEMENT BY APPLICANT First Named Inventor Edwin R. Chapman Art Unit 1645 (Use as many sheets as necessary) **Examiner Name** Attorney Docket Number 960296.99004

4

Sheet 4

Examiner Initials*	ials* No. the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volunto-issue number(s), publisher, city and/or country where published.						
M	21	C.T. WANG, et al. Synaptotagmin modulation of fusion pore kinetics in regulated exocytosis of dense-core vesicles. Science 294: 1111-15 (2001).					
	22	GenBank Accession No. P24506.					
	23	GenBank Accession No. P24505.					
	24	GenBank Accession No. P47191.					
	25	GenBank Accession No. NP_005630.					
	26	GenBank Accession No.X52772.					
	27	GenBank Accession No. D37793.					
	28	GenBank Accession No. D37792.					
	29	GenBank Accession No. M64488.					
	30	GenBank'Accession No. Q8N910.					

Examiner Considered Signature

Date

^{*}EXAMINER: Initial if reference considered, whether or not citation/s in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation is attached.

1 Applicant's unique citation is attached.

1 Applicant's unique citation is attached.

1 Applicant's unique citation is attached.

1 Applicant's unique

JUL 2 2 2005 TOTA TRADE

Signature

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/695,577 Filing Date October 28, 2003 INFORMATION DISCLOSURE First Named Inventor Edward R. Chapman STATEMENT BY APPLICANT Art Unit 1645 N/A **Examiner Name** 960296.99004 Attorney Docket Number Sheet 1

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.	Documen Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (# Incom)			
		US-	\		
		US-			
		US-			
-		US-			
	<u> </u>	US-			
	 	US-			
		US-			
		US-			
	T	US-			
	1	US-		,	
	 	US-			

Foreign Patent Document	IGN PATENT DOCU			
roteight ratem boomism	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Cotumns, Lines, Where Relevant Passages	۳.
Country Code ³ "Number ⁴ "Kind Code ⁸ (if known)	MM-DD-YYYY		Of Relevant Figures Appear	ļ.
			k	
// //				上
///////////////////////////////////////	/		7	<u>_</u>
	Country Code ³ Number ⁴ 'Kind Code ³ (# known)	Country Code ³ "Number ⁴ "Kind Code ³ (# known) MM-DD-YYYY	Country Code ³ Number ⁴ Xind Code ³ (if known) MM-DD-YYYY Date	Country Code ³ Number ⁴ 'Kind Code ³ (# known)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation/if not in conformance and not considered, Include copy of this form with next/communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspio.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Considered



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known		
Substitute for form 1449/PTO				Application Number	10/695,577	
INFORMATION DISCLOSURE				Filing Date	October 28, 2003	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Edward R. Chapman	
				Art Unit	1645	
	(Use as many she	ets es n	ecessary)	Examiner Name	NA FORD	
Sheet	2	of	2	Attorney Docket Number	960296.99004	

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
M		M. Fukuda, et al., "Inositol-1,3,4,5-tetrakisphosphate Binding to C2B Domain of IP4BP/Synaptotagmin II," J. Biol. Chem. 269(46):29206-29211, 1994.	
		J. T. Littleton and H. J. Bellen, "Synaptotagmin Controls and Modulates Synaptic-vesicle Fusion in a Ca2+-dependent Manner," TINS 18(4):177-183, 1995.	
		W. D. Matthew, et al., "Identification of a Synaptic Vescile-specific Membrane Protein with a Wide Distribution in Neuronal and Neurosecretory Tissue," J. Cell Biol. 91:257-269, 1981.	
1		Y. Shoji-Kasai, et al., "Neurotransmitter Release from Synaptotagmin-deficient Clonal Variants of PC12 Cells," Science 256(5065):1820-1823, 1992.	
	ļ <u>.</u>		
			_
Examiner	T	11/21 Date 11/21 18	
Signature		Considered 1700	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.